PROCEPT BioRobotics Corporation PRCT

Company Overview

PROCEPT BioRobotics Corporation is a U.S.-based medical technology company focused on developing and commercializing robotic solutions for urology, specifically the surgical treatment of benign prostatic hyperplasia (BPH). The company operates within the medical devices and surgical robotics industries, addressing a large and growing patient population affected by lower urinary tract symptoms due to prostate enlargement.

The company’s primary revenue driver is the AQUABEAM® Robotic System, which enables Aquablation® therapy, a minimally invasive, image-guided surgical procedure for BPH. PROCEPT is positioned as a differentiated alternative to traditional BPH treatments by combining real-time imaging, robotics, and automated tissue resection. Founded in 2007, the company progressed from early clinical development through FDA clearance, completed an initial public offering in 2021, and has since focused on commercial expansion and clinical adoption.